前收市價 | 25.65 |
開市 | 25.65 |
買盤 | 19.15 |
賣出價 | 21.00 |
拍板 | 135.00 |
到期日 | 2026-01-16 |
今日波幅 | 25.65 - 25.65 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 453 |
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.